Ruthenium Complexes as Promising Candidates against Lung Cancer

被引：55

作者：

Sun, Qi ^{[1
]}

Li, Yingsi ^{[1
]}

Shi, Hongdong ^{[2
]}

Wang, Yi ^{[3
]}

Zhang, Jitian ^{[4
]}

Zhang, Qianling ^{[2
]}

机构：

[1] Shenzhen Univ, Hlth Sci Ctr, Int Canc Ctr,Dept Pharmacol, Guangdong Key Lab Genome Stabil & Dis Prevent, Shenzhen 518060, Peoples R China

[2] Shenzhen Univ, Coll Chem & Environm Engn, Shenzhen 518060, Peoples R China

[3] East China Univ Sci & Technol, Sch Chem & Mol Engn, Key Lab Adv Mat MOE, Shanghai 200237, Peoples R China

[4] Univ Hong Kong, Shenzhen Hosp, Dept Surg, Haiyuan 1st Rd, Shenzhen 518053, Peoples R China

来源：

MOLECULES | 2021年 / 26卷 / 15期

基金：

中国国家自然科学基金;

关键词：

Ruthenium complexes; lung cancer; IN-VITRO CYTOTOXICITY; NAMI-A; CELL-DEATH; PHASE-I; ANTICANCER AGENT; SERUM-ALBUMIN; APOPTOSIS; NECROPTOSIS; METASTASIS; MECHANISM;

D O I：

10.3390/molecules26154389

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Lung cancer is one of the most common malignancies with the highest mortality rate and the second-highest incidence rate after breast cancer, posing a serious threat to human health. The accidental discovery of the antitumor properties of cisplatin in the early 1960s aroused a growing interest in metal-based compounds for cancer treatment. However, the clinical application of cisplatin is limited by serious side effects and drug resistance. Therefore, other transition metal complexes have been developed for the treatment of different malignant cancers. Among them, Ru(II/III)-based complexes have emerged as promising anticancer drug candidates due to their potential anticancer properties and selective cytotoxic activity. In this review, we summarized the latest developments of Ru(II/III) complexes against lung cancer, focusing mainly on the mechanisms of their biological activities, including induction of apoptosis, necroptosis, autophagy, cell cycle arrest, inhibition of cell proliferation, and invasion and metastasis of lung cancer cells.

引用

页数：20

共 121 条

[1] Ruthenium antimetastatic agents [J].